ArticleCureus2025
Chromophobe Renal Cell Carcinoma With Sarcomatoid Differentiation: A Case Report and Review of the Literature.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromophobe renal cell carcinoma is a rare entity with an excellent prognosis compared with clear renal cell carcinoma and is characterized by distinct molecular and genetic specificity. The presence of a sarcomatoid component is an uncommon phenomenon, which indicates a high risk of metastasis and a poor prognosis. We present the case of a 44-year-old patient with chromophobe renal cell carcinoma with a sarcomatoid component. Therapeutic management presents a significant challenge given the absence of standards of care for this rare entity. The current treatments are based on vascular endothelial growth factor tyrosine kinase inhibitors, mammalian target of rapamycin pathway inhibitors, and immune checkpoint inhibitors. Close monitoring based on clinical, biological, and radiological examinations is necessary for rapid and appropriate interventions. Moreover, this histological variant represents a major clinical challenge, not only because of its aggressive behavior but also due to the absence of specific clinical manifestations and its frequent incidental discovery at an advanced stage, further complicating early diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.